BiotechTV

@BiotechTV • 11,822 subscribers

Daily biotech news, content, and exclusive interviews.

Videos

sweetdream.ai

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Private Show

Join now for exclusive access

Free preview available • Premium content

10,996,973 views • 5 months ago

37,771 views • 12 days ago

35,724 views • 26 days ago

43,941 views • 1 month ago

28,217 views • 26 days ago

98,276 views • 9 months ago

85,263 views • 8 months ago

73,893 views • 9 months ago

36,428 views • 5 months ago

13,083 views • 1 month ago

20,584 views • 2 months ago

68,717 views • 1 year ago

22,305 views • 4 months ago

20,919 views • 4 months ago

29,397 views • 8 months ago

17,355 views • 4 months ago

12,238 views • 3 months ago

20,700 views • 6 months ago

20,285 views • 6 months ago

37,174 views • 1 year ago

Live Cam

BiotechTV

Videos

Watch Anya Live

𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video:

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Barclays Investment Bank Biotech Analyst Ellie Merle previews this weekend's highly anticipated cancer vaccine data from Merck and Moderna at ESMO. She sees scenarios for the stock ranging from $100 to mid $400's. $MRK $MRNA Full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Eli Lilly and Company CEO Dave A Ricks discusses GLP-1's, Alzheimer's, business development, and more. Full video:

𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞: Sarah Tabrizi of University College London discusses her experience as an investigator on UniQure's Huntington's Disease gene therapy, AMT-130. Oxford-Harrington Rare Disease Centre

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Eli Lilly and Company's Dave A Ricks shares his thoughts on deals and business development. $LLY Watch the full interview here:

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Meeting spaces around Union Square are so expensive during JPM that one venture capital firm decided to host its meetings this week on a van roving around town. Say hello to THE HATTEBUS.

𝐄𝐩𝐢𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐬: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder &amp; President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: AstraZeneca's CEO Pascal Soriot shares his take on M&amp;A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

𝐇𝐂𝐖 𝟐𝟎𝟐𝟔: With an in-human proof of concept in hand from a rare condition, Prime Medicine is ready to go broader in new indications. $PRME Full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Renowned scientist and entrepreneur Greg Verdine announced $263M in new funding for his company LifeMine Therapeutics. Participating investors include names like Bezos and Gates. See the full interview:

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!

𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video:

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:

𝐔.𝐒. 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐒𝐮𝐦𝐦𝐢𝐭: Alexis Borisy shares his take on one of today's biggest debates in biotech, the impact of China on the U.S. biotech sector.

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐌&amp;𝐀 𝐍𝐞𝐰𝐬: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder &amp; CEO Michael Torres tells us.

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:

𝐄𝐩𝐢𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐬: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐌&𝐀 𝐍𝐞𝐰𝐬: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.